Archives

  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): ...

    2025-11-30

    DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid): Precision Chloride Channel Blocker for Research

    Executive Summary: DIDS is a highly specific anion transport inhibitor and chloride channel blocker, exhibiting robust inhibition of ClC-Ka and ClC-ec1 channels at sub-millimolar concentrations (IC50: 100 μM and 300 μM, respectively) [APExBIO]. It suppresses spontaneous transient inward currents (STICs) in smooth muscle cells and induces vasodilation of pressure-constricted cerebral arteries with an IC50 of 69 ± 14 μM. DIDS modulates TRPV1 channel activity in dorsal root ganglion neurons and enhances tumor growth delay under hyperthermia, particularly in combination with amiloride. It also confers neuroprotection in ischemia-hypoxia by inhibiting ClC-2 channels and reducing apoptosis markers. These properties make DIDS a validated research tool for chloride channel inhibition, vascular physiology, neuroprotection, and cancer models (Conod et al., 2022).

    Biological Rationale

    Chloride channels are fundamental to cellular homeostasis, volume regulation, and signal transduction. Dysregulated chloride flux is implicated in vascular constriction, neurodegenerative disease, and tumor progression [DOI]. DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is used as a research-grade anion transport inhibitor to probe these processes. By selectively blocking ClC-type and related chloride channels, DIDS enables mechanistic dissection of ion transport in excitable and non-excitable cells. The compound’s broad but quantifiable selectivity profile makes it essential for dissecting chloride-dependent pathophysiology in cancer, neurodegeneration, and vascular biology.

    Mechanism of Action of DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid)

    DIDS acts by covalently modifying lysine residues in the extracellular domain of chloride channels, leading to sustained inhibition of anion conductance [APExBIO]. The compound exhibits high affinity for the ClC-Ka channel (IC50: 100 μM) and the bacterial ClC-ec1 Cl-/H+ exchanger (IC50: ~300 μM). In muscle and neuronal models, DIDS reduces spontaneous transient inward currents (STICs) in a concentration-dependent manner. It modulates TRPV1 channel function, potentiating agonist-induced currents in dorsal root ganglion (DRG) neurons. DIDS also inhibits ClC-2 in white matter, reducing ROS, iNOS, TNF-α, and caspase-3-positive cell populations during ischemic-hypoxic injury. The durable covalent interaction distinguishes DIDS from reversible small-molecule antagonists, resulting in persistent chloride flux suppression until protein turnover.

    Evidence & Benchmarks

    • DIDS inhibits ClC-Ka chloride channel activity with an IC50 of 100 μM at pH 7.4 (APExBIO, link).
    • ClC-ec1 Cl-/H+ exchanger is blocked by DIDS with an IC50 of ~300 μM under physiological ionic conditions (APExBIO).
    • DIDS induces vasodilation in pressure-constricted cerebral artery smooth muscle cells (IC50: 69 ± 14 μM at 37°C, pH 7.4) (DOI).
    • Reduces STICs in muscle cells in a dose-dependent manner (1–100 μM; in vitro electrophysiology) (DOI).
    • DIDS enhances capsaicin- and low pH-induced TRPV1 currents in DRG neurons (whole-cell patch clamp, 10–100 μM) (internal).
    • In vivo, DIDS (10–50 mg/kg) with amiloride increases hyperthermia-induced tumor growth delay in mouse models (DOI).
    • Ameliorates ischemia-hypoxia-induced white matter damage in neonatal rats by ClC-2 inhibition (10–100 μM, pH 7.4) (internal).
    • Reduces ROS, iNOS, TNF-α, and caspase-3+ cells in ischemic white matter (immunohistochemistry, n=6/group) (DOI).

    This article extends the mechanistic depth of DIDS: Mechanistic Dissection and Translational Implications by providing new quantitative application parameters and updated in vivo benchmarks. For further context on translational models, see DIDS: Multifaceted Roles in Chloride Channel Modulation, which this article updates with recent neuroprotection and tumor suppression data.

    Applications, Limits & Misconceptions

    DIDS is validated in a spectrum of research applications:

    • Chloride channel inhibition in electrophysiological and biochemical assays.
    • Vascular physiology studies, including cerebral artery tone modulation.
    • Neuroprotection models for ischemia-hypoxia and white matter injury.
    • Cancer research, including hyperthermia-enhanced tumor suppression.
    • Apoptosis and caspase-3 signaling pathway modulation.

    However, DIDS has limitations:

    • It is not selective for a single chloride channel subtype; off-target effects may occur at higher concentrations.
    • It is insoluble in water, ethanol, and DMSO below 10 mM, requiring specific solubilization steps (APExBIO).
    • Not suitable for long-term stock solution storage; freshly prepared aliquots recommended for reproducibility.
    • DIDS is not intended for therapeutic use in humans or animals.

    Common Pitfalls or Misconceptions

    • DIDS is not a selective tool for a single chloride channel: Multiple ClC and non-ClC anion channels may be affected at micromolar concentrations.
    • It is not water-soluble: Attempts to dissolve DIDS in aqueous buffers without pre-dissolving in DMSO (≥10 mM) or heating will fail.
    • Long-term storage in solution is not advised: Degradation and precipitation can occur below -20°C over time.
    • In vivo pharmacokinetics are not fully characterized: Results may not translate directly to human clinical settings.
    • Not a therapeutic agent: DIDS is a research reagent, not approved for clinical or diagnostic use.

    Workflow Integration & Parameters

    For optimal use, DIDS (APExBIO B7675) should be dissolved in DMSO at concentrations ≥10 mM. Solubility can be enhanced by warming to 37°C or using an ultrasonic bath. Aliquots should be stored below -20°C and protected from light. Working solutions should be prepared fresh for each experiment. Typical working concentrations for in vitro assays range from 1–300 μM, depending on the chloride channel subtype and cell system. In vivo research uses dosing regimens between 10–50 mg/kg, with administration routes and timing tailored to the model. Refer to the B7675 kit page for detailed handling instructions.

    For troubleshooting, see DIDS: Applied Innovations in Chloride Channel Blockade and Workflow, which focuses on practical solutions for compound handling and experiment design, while this article provides updated benchmarks and mechanistic context.

    Conclusion & Outlook

    DIDS (4,4'-Diisothiocyanostilbene-2,2'-disulfonic Acid) is a gold-standard anion transport inhibitor and chloride channel blocker, enabling high-fidelity dissection of ion channel function in research models. It offers validated efficacy in vascular, neuroprotective, and cancer hyperthermia contexts, but requires careful solubilization and concentration management for optimal results. Future research may clarify its potential in combinatorial models and emerging metastasis paradigms, as reflected in recent mechanistic studies (Conod et al., 2022). For reagent sourcing and further technical details, APExBIO provides comprehensive support for the B7675 kit.